List of Excipients in Branded Drug ROSUVASTATIN

Generic Drugs Containing ROSUVASTATIN

Company	Ingredient	NDC	Excipient
AiPing Pharmaceutical Inc	rosuvastatin	11788-130	CELLULOSE, MICROCRYSTALLINE
AiPing Pharmaceutical Inc	rosuvastatin	11788-130	FERRIC OXIDE RED
AiPing Pharmaceutical Inc	rosuvastatin	11788-130	FERRIC OXIDE YELLOW
AiPing Pharmaceutical Inc	rosuvastatin	11788-130	HYPROMELLOSE 2910
AiPing Pharmaceutical Inc	rosuvastatin	11788-130	LACTOSE MONOHYDRATE
AiPing Pharmaceutical Inc	rosuvastatin	11788-130	MAGNESIUM STEARATE
AiPing Pharmaceutical Inc	rosuvastatin	11788-130	POLACRILIN POTASSIUM

What are the Most Frequently-Used Excipients in ROSUVASTATIN?

# Of NDCs	Excipient
8	ANHYDROUS LACTOSE
1	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
1	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
1	CARBOXYMETHYLCELLULOSE CALCIUM
67	CELLULOSE, MICROCRYSTALLINE
1	CI 77491
4	CI 77891

Rosuvastatin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Rosuvastatin is a mature, high-volume statin with broad generic availability and limited need for complex solubility technologies. The strongest formulation opportunities are cost-efficient tablets, stability-controlled products, fixed-dose combinations, orally disintegrating formats, and differentiated products for patients with swallowing or adherence difficulties. The main technical issue is controlling rosuvastatin calcium stability while maintaining rapid dissolution and low manufacturing cost.

What is the commercial status of rosuvastatin?

Rosuvastatin is a synthetic HMG-CoA reductase inhibitor marketed originally as Crestor by AstraZeneca. The active pharmaceutical ingredient is generally supplied as rosuvastatin calcium, although strength is expressed as rosuvastatin equivalent.

The FDA approved Crestor in the United States in 2003. Rosuvastatin is available in 5 mg, 10 mg, 20 mg, and 40 mg tablets. Generic rosuvastatin calcium products are approved through the abbreviated new drug application pathway and compete primarily on price, supply reliability, pharmacy contracting, and manufacturing cost.[1]

Commercial factor	Rosuvastatin position
Drug class	Statin, HMG-CoA reductase inhibitor
Reference product	Crestor
Originator	AstraZeneca
API form	Rosuvastatin calcium
Common dosage forms	Immediate-release tablets
U.S. regulatory pathway for generics	ANDA
Biosimilar pathway	Not applicable
Main demand drivers	Cardiovascular risk reduction, dyslipidemia, diabetes, secondary prevention
Main generic differentiators	Price, supply, tablet size, excipient profile, combination products
Primary formulation challenge	Stability and dissolution control
Primary commercial risk	Commodity pricing and limited differentiation

Crestor historically generated multibillion-dollar annual sales for AstraZeneca before generic erosion. AstraZeneca reported Crestor sales of approximately $5 billion in the middle of the 2010s, making rosuvastatin one of the largest statin franchise products before loss of exclusivity.[2]

What excipients are used in rosuvastatin tablets?

The Crestor formulation uses conventional direct-compression or wet-granulation tablet excipients. The U.S. prescribing information identifies lactose monohydrate, microcrystalline cellulose, tribasic calcium phosphate, crospovidone, and magnesium stearate in the tablet core. The film coating includes hypromellose, triacetin, titanium dioxide, and colorants that vary by strength.[1]

Excipient category	Typical examples	Function
Diluent	Lactose monohydrate, microcrystalline cellulose, calcium phosphate	Tablet mass, compressibility
Disintegrant	Crospovidone	Rapid tablet breakup
Lubricant	Magnesium stearate	Ejection and tooling protection
Binder or processing aid	Microcrystalline cellulose, povidone where used	Granule and tablet strength
Film former	Hypromellose	Coating integrity
Plasticizer	Triacetin, polyethylene glycol in some products	Coating flexibility
Opacifier	Titanium dioxide	Appearance and light protection
Colorant	Iron oxides or approved dyes	Strength identification

Generic manufacturers do not need to duplicate the Crestor excipient system. They must meet applicable quality, bioequivalence, stability, dissolution, and labeling requirements. This creates room for excipient substitution, provided that the formulation remains pharmaceutically equivalent and does not introduce safety or performance problems.

Which excipients are most important for rosuvastatin stability?

The highest-value excipient decision is control of the formulation microenvironment. Rosuvastatin calcium can be sensitive to formulation conditions, including pH, moisture, heat, and interactions with reactive or acidic excipients. Formulators should screen excipients for chemical compatibility rather than select them solely from standard immediate-release templates.

pH and microenvironment control

Alkaline or near-neutral microenvironments may improve stability relative to acidic conditions. Candidate materials can include calcium phosphate, alkaline buffers, carbonate or bicarbonate systems, and selected inorganic salts. The appropriate system depends on impurity formation, tablet hardness, dissolution, and long-term stability.

An alkaline excipient package can create problems if used at excessive levels. Potential effects include slower disintegration, altered dissolution, hygroscopicity, poor flow, and interaction with the calcium salt. The commercial objective is not to maximize alkalinity. It is to maintain an acceptable microenvironment without adding unnecessary formulation complexity.

Moisture control

Moisture can affect tablet hardness, disintegration, coating integrity, and impurity growth. Moisture-sensitive strategies include:

• Low-moisture excipient grades.
• Controlled humidity during granulation and compression.
• High-barrier blister packaging.
• Desiccant-equipped bottles where justified.
• Film coatings that limit water ingress.
• Avoidance of hygroscopic excipients unless they provide a clear performance benefit.

Microcrystalline cellulose and lactose are widely used, but grade selection matters. Particle size, bulk density, moisture content, and supplier variability can change compression behavior and dissolution.

Oxidative and reactive impurity control

Excipient peroxides, aldehydes, and trace metals can contribute to degradation in susceptible drug products. The risk assessment should cover:

• Peroxide levels in povidone and crospovidone.
• Reducing sugars and reactive impurities in carbohydrate excipients.
• Trace metals in inorganic salts.
• Residual solvents in functional excipients.
• Interaction between colorants and the active ingredient.
• Packaging-related leachables.

A supplier qualification program should include excipient-specific impurity limits, not only compliance with pharmacopeial identity and purity tests.

What formulation strategy offers the lowest commercial risk?

A conventional immediate-release film-coated tablet remains the lowest-risk strategy for most manufacturers. It has an established regulatory pathway, broad prescriber familiarity, relatively low manufacturing cost, and extensive bioequivalence precedent.

Baseline generic tablet

The baseline formulation should prioritize:

1. Rapid and reproducible disintegration.
2. Dissolution matching across all strengths.
3. Stable assay and impurity profile.
4. Low tablet weight.
5. Simple scale-up.
6. Global excipient availability.
7. Low coating and packaging costs.

A direct-compression formulation may reduce manufacturing steps, but it requires sufficiently uniform API distribution and favorable flow properties. Wet granulation may improve content uniformity and compression but increases process complexity, moisture exposure, and validation burden.

Excipient platform options

Strategy	Benefits	Main risks	Commercial fit
Lactose/MCC/crospovidone tablet	Low cost, familiar, scalable	Possible reactive impurity and supplier variability	Standard generic
Calcium phosphate-based tablet	Supports robust compression and alkaline microenvironment	Higher density, possible dissolution effects	Stability-focused generic
Low-moisture formulation	Better control of water-related degradation	May increase cost	Humid markets
Hypromellose film coat	Established, scalable, strong appearance	Coating process and colorant controls	Broad commercial use
Povidone-based granulation	Improved granule strength	Peroxide and moisture concerns	Difficult compression
Mannitol-based tablet	Patient-friendly, low-sugar positioning	Higher cost and possible friability	Premium or ODT product
Co-processed excipient system	Better flow and compression	Supplier dependence and higher cost	High-throughput manufacturing

What formulation patents protect rosuvastatin products?

Rosuvastatin’s principal compound and product protections were filed before the product became a generic-market medicine. The original rosuvastatin compound patent family was associated with Shionogi and licensed to AstraZeneca. U.S. Patent No. 5,260,440 covered rosuvastatin-related compounds and was listed historically among the core protections for the product.[3]

Later patent activity addressed pharmaceutical compositions, salts, formulations, and methods of use. Many of the most commercially important U.S. protections have expired, which allowed ANDA-based generic entry. Current commercial barriers are therefore more likely to arise from manufacturing know-how, supply contracts, regulatory execution, and differentiated dosage-form patents than from the original compound patent.

Protection category	Strategic relevance
Rosuvastatin compound patents	Historical blocking rights; expired in major markets
Rosuvastatin calcium salt	Supports API and product definition
Stable composition patents	May protect excipient combinations or processing conditions
Method-of-use patents	Limited value where statin indications are broadly established
Fixed-dose combination patents	Relevant for rosuvastatin plus ezetimibe, amlodipine, or other agents
ODT or multiparticulate patents	Potentially relevant to differentiated products
Manufacturing patents	Can protect impurity control, crystallization, or scale-up processes
Packaging and stability know-how	Usually trade-secret or product-specific rather than broad blocking IP

Patent protection for a new excipient combination must be assessed against written-description, enablement, obviousness, and freedom-to-operate standards. A formulation that simply replaces one conventional filler with another is unlikely to provide strong exclusionary value without a demonstrated stability, dissolution, bioavailability, or manufacturing advantage.

When did rosuvastatin lose exclusivity?

Rosuvastatin lost practical U.S. market exclusivity after the expiration or resolution of the principal patent barriers and the entry of approved generic products. AstraZeneca faced generic competition in the United States during the mid-2010s. The regulatory exclusivity period for the original new chemical entity had expired well before broad generic commercialization.[1,4]

Milestone	Approximate timing
Rosuvastatin licensed by AstraZeneca from Shionogi	Late 1990s
U.S. Crestor approval	2003
NCE exclusivity period	Expired before generic launch
Major U.S. generic entry	Mid-2010s
Current market structure	Multiple generic manufacturers and low-cost suppliers

The exact status of individual Orange Book listings depends on the reference-product edition and patent listing history. The key commercial conclusion is that rosuvastatin is no longer protected by a broad, enforceable compound-level exclusivity barrier in the United States.

What is the Orange Book status of rosuvastatin?

Rosuvastatin products are listed in the FDA Orange Book as approved prescription tablets, with the reference product identified as Crestor and multiple generic equivalents approved under ANDAs.[4] Orange Book listings distinguish therapeutic equivalence from patent certification status. They do not establish that every formulation or manufacturing process is free of third-party patent risk.

For a new rosuvastatin product, the relevant regulatory questions include:

• Whether the product is pharmaceutically equivalent to the reference listed drug.
• Whether the dosage form and strength match the reference product.
• Whether inactive ingredients create safety concerns.
• Whether the product requires a Paragraph IV certification.
• Whether a listed method-of-use patent remains relevant.
• Whether the product is an ANDA, 505(b)(2), or full NDA candidate.

Paragraph IV challenges

Paragraph IV litigation was historically important for rosuvastatin because early generic applicants challenged remaining listed patents to obtain earlier entry. Once the key listed patents expired or were resolved, the litigation risk shifted from core product patents to formulation, combination, manufacturing, and process patents.

For a new ANDA applicant, Paragraph IV risk is now generally narrower than it was before generic entry. A formulation with novel excipients, modified release, a new route, or a new combination may fall outside the standard ANDA framework and require a different patent and regulatory analysis.

Are biosimilars a risk for rosuvastatin?

No. Rosuvastatin is a small-molecule drug, not a biologic. Competitors enter through generic-drug pathways rather than biosimilar applications. The relevant competitive risks are ANDA approvals, authorized generics, private-label supply, and differentiated small-molecule products.

This distinction affects development economics. A rosuvastatin manufacturer does not need to reproduce a biologic reference product’s higher-complexity analytical package. It must establish pharmaceutical equivalence and bioequivalence under the applicable FDA requirements.[5]

What commercial opportunities exist for rosuvastatin excipient innovation?

The largest opportunities are not in basic generic tablets. They are in patient convenience, combination therapy, supply-chain differentiation, and regional formulation needs.

Orally disintegrating tablets

An ODT could target patients with dysphagia, older adults, and patients with poor adherence. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking systems are possible excipient tools.

The commercial obstacles are meaningful:

• Rosuvastatin has a bitter taste.
• The dose can reach 40 mg.
• ODT tablets may be larger than standard tablets.
• Moisture protection is critical.
• Packaging costs can exceed those of conventional bottles.
• Bioequivalence must be demonstrated for the finished dosage form.

An ODT is more commercially attractive where a payer, hospital system, or brand partner values adherence or administration convenience.

Fixed-dose combinations

Rosuvastatin is commercially suited to fixed-dose combinations because dyslipidemia patients often receive more than one cardiovascular medicine. Potential combinations include:

• Rosuvastatin and ezetimibe.
• Rosuvastatin and amlodipine.
• Rosuvastatin and antihypertensive agents.
• Rosuvastatin and antidiabetic or cardiovascular-risk therapies.

Combination products create stronger differentiation than a new excipient in a single-ingredient tablet. They also create formulation challenges involving dose ratio, chemical compatibility, dissolution of each active, and separate patent positions.

Sprinkle and multiparticulate products

Multiparticulate products may be useful for patients who cannot swallow tablets. They can also support flexible dosing and taste masking. The main technical barriers are uniform drug loading, dose recovery from food or liquid, stability after opening, and food-effect evaluation.

Clean-label and allergen-sensitive products

Lactose-free, sugar-free, colorant-free, and vegetarian formulations can support pharmacy and institutional procurement programs. These products are unlikely to command large premiums in standard retail generic channels, but they can improve contract eligibility and reduce patient switching caused by intolerance or excipient preferences.

Regional supply and dual sourcing

Excipient strategy can support geographic expansion. A formulation dependent on one specialty excipient supplier has a higher supply risk than a formulation using globally available grades of microcrystalline cellulose, calcium phosphate, crospovidone, and hypromellose.

For emerging markets, the strongest product may be a stable, low-cost tablet with:

• Low tablet weight.
• No cold chain.
• Robust packaging.
• Wide humidity tolerance.
• Common excipients.
• Simple analytical release testing.

How strong is the rosuvastatin patent estate?

The broad patent estate is weak from a generic-entry perspective because the key compound-level rights have expired and multiple generic products are already marketed. The remaining IP value is concentrated in narrower claims.

IP asset	Strength today	Commercial implication
Core rosuvastatin compound	Low after expiry	Does not block standard generics
Conventional immediate-release tablet	Low to moderate	Limited room for broad exclusivity
Novel stability package	Moderate if data-supported	May protect a specific formulation
ODT or sprinkle product	Moderate	Potential differentiated product
Combination product	Moderate to strong, depending on claims	Supports branded or specialty generic positioning
API process and impurity control	Moderate	Can create manufacturing advantages
Trade secrets	Relevant	Important for scale-up and yield
Method of use	Generally limited	Most major indications are established

A defensible formulation patent should link the excipient system to a measurable technical result, such as reduced degradation, improved dissolution after storage, improved bioavailability, or reliable performance under high humidity. Patent claims based only on a routine substitution of excipients are vulnerable to obviousness challenges.

Which companies are challenging or competing with rosuvastatin?

Competition comes from several groups:

1. Large generic companies with broad pharmacy distribution.
2. Contract manufacturers supplying private-label products.
3. Regional manufacturers in emerging markets.
4. Combination-product developers.
5. Originator companies selling branded or authorized-generic products.
6. API manufacturers competing on purity, yield, and supply continuity.

The principal therapeutic competitors are atorvastatin, simvastatin, pravastatin, and pitavastatin. Atorvastatin has the largest direct generic overlap in many markets. Rosuvastatin retains commercial value because of its potency, low-density lipoprotein reduction, and use at lower milligram doses than several competing statins.[6]

What generic launch risks exist?

A conventional rosuvastatin tablet has a low regulatory and technical barrier, but launch economics remain difficult.

The main risks are:

• Price erosion from multiple ANDA holders.
• API supply interruptions.
• Batch failures caused by impurity growth.
• Dissolution failure after accelerated stability testing.
• Excipient supplier changes.
• Inadequate segregation of strength-specific colorants.
• Packaging failures in hot and humid markets.
• Reimbursement exclusion.
• Low net price after wholesaler and pharmacy deductions.
• Product liability exposure from labeling or contamination events.

A new entrant should avoid competing only on tablet price. Better economics may come from a differentiated dosage form, a combination product, a regional license, a reliable API-excipient supply package, or a hospital contract requiring dual sourcing.

What licensing opportunities exist for rosuvastatin?

The most credible licensing opportunities involve differentiated products rather than ordinary tablets. Candidates include:

• Rights to a stable formulation platform.
• Regional commercialization rights.
• Fixed-dose combinations.
• ODT and sprinkle technologies.
• High-throughput manufacturing processes.
• Low-cost formulations for public procurement.
• API supply agreements with validated impurity controls.

A conventional generic tablet may still support licensing where the licensee has a distribution advantage or regulatory footprint. The formulation itself is unlikely to command a high royalty unless it has a defensible patent, a clear stability advantage, or preferential market access.

Key Takeaways

• Rosuvastatin is a mature small-molecule market with extensive generic competition.
• The original compound-level exclusivity has expired in major markets.
• The most practical formulation is a conventional immediate-release film-coated tablet.
• Calcium phosphate, microcrystalline cellulose, crospovidone, lactose, and hypromellose are established excipient choices.
• Stability screening should focus on pH, moisture, peroxides, trace metals, and reactive excipient impurities.
• Novel excipient combinations have limited value unless they produce measurable stability, dissolution, or manufacturing benefits.
• ODTs, sprinkle products, and fixed-dose combinations offer the strongest differentiation opportunities.
• Rosuvastatin has no biosimilar risk because it is a small-molecule drug.
• Current commercial barriers are more likely to involve price erosion, supply reliability, formulation execution, and narrow formulation patents than compound patents.
• Licensing value is highest for differentiated products, combination therapies, regional access, and validated supply platforms.

FAQs

Can rosuvastatin tablets be formulated without lactose?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, calcium phosphate, starch-based materials, or co-processed excipients. The replacement must be evaluated for stability, compression, dissolution, and bioequivalence.

Is calcium phosphate required in rosuvastatin tablets?

No. Calcium phosphate is used in the Crestor formulation and some generic formulations, but it is not universally required. Other diluents may be used if the finished product meets applicable quality and equivalence requirements.

Does rosuvastatin need a solubility-enhancing excipient?

Usually not for a standard immediate-release product. The more important development objectives are rapid dissolution, content uniformity, chemical stability, and robust performance during storage.

Can rosuvastatin be developed as a chewable tablet?

Yes, but taste masking is a central development issue. The developer must also address dose size, mechanical strength, dissolution, patient acceptability, and the applicable regulatory pathway.

Is a rosuvastatin formulation patentable?

Potentially. Patentability is stronger when a defined excipient system produces an unexpected and measurable result, such as improved stability under stress, improved dissolution after storage, or a clinically relevant delivery benefit.

References

1. U.S. Food and Drug Administration. (2023). Crestor (rosuvastatin calcium) tablets: Prescribing information. AstraZeneca Pharmaceuticals LP.

2. AstraZeneca PLC. (2015). Annual report and Form 20-F 2014. AstraZeneca.

3. U.S. Patent No. 5,260,440. (1993). Trans-6-[2-(substituted pyrrol-1-yl)alkyl]-4-hydroxy-pyran-2-one derivatives and their pharmaceutical use. U.S. Patent and Trademark Office.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2023). ANDA submissions: Content and format. FDA.

6. U.S. Food and Drug Administration. (2020). Statins and cardiovascular risk reduction: Drug safety and clinical information. FDA.